These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30535292)

  • 61. Facial ulceration in a patient with Crohn's disease.
    Huang B; Melmed GY; Shih DQ
    Gastroenterology; 2012 May; 142(5):1071, 1258. PubMed ID: 22440954
    [No Abstract]   [Full Text] [Related]  

  • 62. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.
    Vernero M; Ribaldone DG; Cariti C; Ribero S; Susca S; Astegiano M; Dapavo P
    J Dermatol; 2020 Jun; 47(6):e216-e217. PubMed ID: 32347562
    [No Abstract]   [Full Text] [Related]  

  • 63. Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases.
    Khurrum Baig M; Marquez H; Nogueras JJ; Weiss EG; Wexner SD
    Colorectal Dis; 2004 Jul; 6(4):250-3. PubMed ID: 15206967
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recalcitrant pyoderma gangrenosum treated with thalidomide.
    Federman GL; Federman DG
    Mayo Clin Proc; 2000 Aug; 75(8):842-4. PubMed ID: 10943240
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Infliximab for a girl with refractory pyoderma gangrenosum].
    Nozawa T; Hara R; Kinoshita J; Sano F; Miyamae T; Imagawa T; Mori M; Hirokado M; Takahashi K; Inayama Y; Yokota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Dec; 31(6):454-9. PubMed ID: 19122376
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Coexistence of pyoderma gangrenosum and Sweet's syndrome in a patient with ulcerative colitis.
    Castro-Fernández M; Sánchez-Muñoz D; Ruíz-Granados E; Merchante N; Corzo J
    Am J Gastroenterol; 2007 Dec; 102(12):2865-6. PubMed ID: 18042124
    [No Abstract]   [Full Text] [Related]  

  • 67. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pyoderma gangrenosum in an infant: A case report and review of the literature.
    Crouse L; McShane D; Morrell DS; Wu EY
    Pediatr Dermatol; 2018 Sep; 35(5):e257-e261. PubMed ID: 29656404
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pyoderma gangrenosum successfully treated with cyclosporin A.
    V'lckova-Laskoska MT; Laskoski DS; Caca-Biljanovska NG; Darkoska JS
    Adv Exp Med Biol; 1999; 455():541-5. PubMed ID: 10599396
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Pyoderma gangrenosum, a nonintestinal manifestation of Lesniowski-Crohn's disease in a 15 years old girl].
    Müller L; Bala G; Kuczyńska R; Czerwionka-Szaflarska M
    Med Wieku Rozwoj; 2006; 10(2):463-73. PubMed ID: 16825717
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two cases of bullous pyoderma gangrenosum complicated by Epstein-Barr virus infection.
    Zhou Y; Chen W; Zhang X; Huang F; Wang D
    Eur J Dermatol; 2018 Jun; 28(3):370-371. PubMed ID: 29952293
    [No Abstract]   [Full Text] [Related]  

  • 72. Refractory pyoderma gangrenosum treated with infliximab in an infant.
    Campos-Muñoz L; Conde-Taboada A; Aleo E; Toledano E; López-Bran E
    Clin Exp Dermatol; 2014 Apr; 39(3):336-9. PubMed ID: 24635074
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of pyoderma gangrenosum with methotrexate.
    Teitel AD
    Cutis; 1996 May; 57(5):326-8. PubMed ID: 8726713
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Finally, recurrent pyoderma gangrenosum treated with Adalimumab: case report and review of the literature.
    Campanati A; Brisigotti V; Ganzetti G; Molinelli E; Giuliodori K; Consales V; Racchini S; Bendia E; Offidani A
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1245-7. PubMed ID: 25200926
    [No Abstract]   [Full Text] [Related]  

  • 75. Peripheral regional aseptic neutrophilic lymphadenopathy associated with pyoderma gangrenosum.
    Al-Niaimi F; Cox NH
    Br J Dermatol; 2009 Nov; 161(5):1206-7. PubMed ID: 19678821
    [No Abstract]   [Full Text] [Related]  

  • 76. Treatment of refractory pyoderma gangrenosum with infliximab in a 17-month-old boy.
    Bobbitt SA; Klaus EM; Stringer E; Chowdhury D; Finlayson L
    Dermatol Online J; 2016 Apr; 22(4):. PubMed ID: 27617462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
    Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
    Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pyoderma gangrenosum as an initial presentation of Crohn's colitis.
    Mountagui A; Al-Dury S
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38110340
    [No Abstract]   [Full Text] [Related]  

  • 79. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
    Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
    Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn's disease: A case report.
    Pender TM; Ayandibu G; Van Voorhees AS
    Dermatol Ther; 2020 Nov; 33(6):e14352. PubMed ID: 32981217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.